Core Viewpoint - China Medical announced that its wholly-owned subsidiary, Hainan Tongyong Sanyang Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for two supplemental applications for injectable L-lysine, which passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical sector [1] - The injectable L-lysine is expected to contribute positively to the company's revenue stream following its market introduction [1] - The successful completion of the consistency evaluation indicates the company's commitment to maintaining high-quality standards in its pharmaceutical offerings [1]

Core Viewpoint - Sairun Pharmaceutical (002898) has issued a warning regarding the risk of delisting due to expected negative profits and revenues for the fiscal year 2024, following a significant revision of its earnings forecast [1][4]. Financial Performance - The company initially projected 2024 revenues between 270 million to 320 million yuan, with a net profit of 4.5 million to 6.5 million yuan, but later revised these figures to revenues of 255 million to 270 million yuan and a net loss of 21 million to 41 million yuan [2][6]. - The revision was attributed to the decision to not recognize certain sales revenues, resulting in a reduction of approximately 39.63 million yuan in revenue and 33.96 million yuan in gross profit [3][6]. Historical Context - Sairun Pharmaceutical has a history of revising its earnings forecasts, having made multiple adjustments from 2021 to 2023, indicating ongoing issues with revenue recognition standards [5][6]. - The company has reported losses in most years since 2020, with only 2023 showing a profit of 9.534 million yuan, while losses for 2020, 2021, and 2022 were 67.22 million, 23.34 million, and 37.31 million yuan respectively [6]. Market Dynamics - The company’s main products contribute significantly to its revenue, but they face intense competition, with numerous generic alternatives available in the market [7]. - Despite winning bids in national drug procurement, the expected revenue growth has not materialized, leading to continued financial pressure [8][9]. Strategic Response - Sairun Pharmaceutical acknowledges the challenges posed by drug price reductions due to centralized procurement and aims to leverage its full industry chain advantages to enhance market presence and profitability [10]. - The company plans to improve its financial reporting and investor communication to restore confidence amid the risk of delisting [10].